Schering Fails To Thwart Securities Suit Over Vytorin
A federal judge will not reconsider his decision to allow a securities suit alleging Schering-Plough Corp. hid or misstated the relatively poor performance of its anti-cholesterol drug Vytorin, even in light...To view the full article, register now.
Already a subscriber? Click here to view full article